Non-Small Cell Lung Cancer: Treatment Options & Specialist Care

Non-small cell lung cancer (NSCLC) includes adenocarcinoma, squamous cell carcinoma and less common types. Treatment depends on the stage, exact pathology, molecular and PD-L1 results, and treatment already received. A new diagnosis and progression after treatment need different discussions.

When NSCLC has not spread to distant parts of the body, treatment with the aim of cure is often still possible. Start with three questions: can the cancer be removed completely, can your body tolerate surgery, and should medicines be given before or after it?

Non-metastatic does not always mean early-stage. Stages I, II and III can all have no distant spread, but the extent of disease in the chest and the treatment plan can differ substantially. Cancer in nearby lymph nodes does not automatically mean stage IV.

My report says stage IIA or IIB. What should I look for?

Stage IIA and IIB depend on tumor size, involvement of nearby structures and lymph nodes. Stage IIA does not always mean node-negative disease. Stage groupings have changed between editions, so share the complete T, N and M findings and the staging edition, rather than just the words “stage II”.

If surgery is possible, why have medicines first?

For selected patients with resectable stage II NSCLC, chemotherapy plus immunotherapy before surgery can be part of the plan. It aims to treat the visible cancer and possible microscopic disease and reduce the risk of recurrence. Medicines first do not mean surgery has been abandoned. Ask how many cycles are planned, when scans will be repeated and how surgery will follow.

Other patients may have surgery first, with further treatment based on the surgical pathology. The sequence depends on lymph nodes, the extent of the tumor, biomarkers and the eligibility criteria for the particular regimen—not the stage II label alone.

If the cancer is removed, why might I need more treatment?

Surgery removes visible disease; medicines afterward aim to reduce the risk of recurrence. Whether platinum-based chemotherapy, targeted therapy or immunotherapy is appropriate depends on lymph nodes, surgical margins, molecular findings, recovery and any treatment already given before surgery. These are not a fixed package that everyone needs in sequence.

If I cannot have surgery, are there other active treatments?

Yes. First establish why surgery is unsuitable, then compare radiotherapy and medicine-based options.

• A relatively localized tumor without lymph-node involvement, but heart or lung health that makes surgery unsuitable: stereotactic body radiotherapy (SBRT/SABR) may be an option.
• Involved lymph nodes or a wider treatment area: the team needs to assess the appropriate radiation field and whether chemotherapy should be included, rather than treating only the lung mass.
• Uncertainty about medicines first or surgery first: a joint review by thoracic surgery, medical oncology and radiation oncology can clarify the complete sequence.

Stage III: operability matters as well as the stage label

Stage III is locally advanced disease. The location and extent of lymph-node involvement, tumor anatomy and fitness determine whether surgery can form part of a combined plan. Stage IIIB is not the same as stage IV. A multidisciplinary review should clarify the treatment goal and sequence before starting.

Unresectable stage III

Patients who can tolerate it are often assessed for definitive chemoradiotherapy, followed by an appropriate consolidation strategy. Biomarkers matter here too: the US osimertinib label includes unresectable stage III disease with EGFR exon 19 deletion or L858R that has not progressed during or after platinum-based chemoradiation. This differs from postoperative treatment and metastatic first-line treatment.

Stage IV: match treatment to the cancer, not just the stage

Stage IV treatment usually aims to control cancer and preserve quality of life. An actionable molecular alteration may open a targeted treatment path; otherwise, histology, PD-L1, health and contraindications help determine an immunotherapy and chemotherapy plan. Brain metastases, pain or a small number of progressing lesions may need local treatment alongside systemic care.

Adenocarcinoma and squamous cell carcinoma are both types of NSCLC. Non-squamous means a type other than squamous cancer; adenocarcinoma belongs in that group. Grade 2 describes how abnormal the cells look under a microscope. It does not mean stage II, which describes how far the cancer has spread.

Immunohistochemistry helps classify the tumor and assess proteins such as PD-L1. A broad sequencing panel looks for genetic alterations; these tests answer different questions. Preserve the full report rather than a message saying only 'gene-positive' or 'immune-positive'.

Match the exact alteration

Treatment-relevant findings can involve EGFR, ALK, ROS1, RET, MET, BRAF, KRAS, HER2/ERBB2 and NTRK, among others. A mutation, fusion, exon-skipping event, amplification and protein overexpression are not interchangeable. EGFR exon 19 deletion or L858R, for example, must not be treated as equivalent to every EGFR exon 20 insertion. A broad panel can help avoid repeated single-gene tests when appropriate.

A negative blood test may not settle the question

Plasma testing can identify tumor DNA without another tissue procedure, but some cancers release little DNA into blood. A negative result may therefore require tissue testing if feasible and clinically useful. The specimen, tumor content, assay coverage and whether fusion detection is included all affect interpretation.

PD-L1 belongs in context

PD-L1 can help choose an immunotherapy strategy, but it does not guarantee response. In advanced disease with a relevant actionable driver, a matched targeted pathway may take priority even when PD-L1 is high. The team should review essential molecular results before starting a regimen when it is clinically safe to wait.

Squamous cell lung cancer is a type of NSCLC. Surgery or radiotherapy may be options for early disease; advanced disease can be treated with immunotherapy, chemotherapy and other options for selected patients. The practical differences are which medicines are suitable, which tests could change the plan and what your body can tolerate.

Which results should be checked before treatment?

These findings need to be considered together; one positive result does not select a medicine on its own.

Can advanced squamous lung cancer be treated with immunotherapy?

Yes. Whether to combine it with chemotherapy depends on the situation. For example, the current US pembrolizumab label includes first-line treatment of metastatic squamous NSCLC with carboplatin and paclitaxel or nab-paclitaxel. This combination indication does not require a positive PD-L1 result.

Some eligible patients may consider immunotherapy alone, depending on the medicine’s criteria, molecular findings, symptoms and how quickly the cancer is growing. High PD-L1 does not automatically make single-agent treatment the best choice. Combination treatment also requires weighing risks such as low blood counts, nerve damage and immune-related inflammation.

Why not use the same drug list as for adenocarcinoma?

• Pemetrexed: commonly used in non-squamous NSCLC; its US label specifically states that it is not indicated for squamous NSCLC.
• Bevacizumab: squamous lung cancer carries a higher risk of serious pulmonary bleeding, so this lung cancer treatment approach is generally not used. That does not mean every medicine affecting blood-vessel growth has the same restrictions.
• Targeted medicines: these require a specific, actionable molecular finding and a match to the drug’s patient group and treatment setting. “Both are lung cancer” or “the same target” is not enough.

What if the cancer grows after chemotherapy or immunotherapy?

Some patients can be assessed for later-line treatment such as docetaxel, an eligible targeted option or a clinical trial. After progression on an immune checkpoint medicine, switching to another similar medicine is not a default effective next step. The next section explains how the sites of progression, previous benefit and testing can guide local treatment or a change in systemic therapy.

First confirm what has changed. Growth at one site, new brain disease and widespread progression are different patterns. Review treatment adherence, dose interruptions, previous benefit and side effects. When the result could change care, a new biopsy or molecular assessment may identify resistance or a change in histology, including transformation to small cell cancer.

A drug with better activity against a specific resistance mechanism, local treatment while preserving a useful systemic medicine, chemotherapy or a clinical trial may be considered in different situations. Do not assume that any new targeted drug is suitable simply because it mentions the same gene.

What happens when Tagrisso (osimertinib) stops working?

The next step depends on where the cancer has progressed, the resistance findings and previous treatment; there is no single replacement for everyone. Bring the original EGFR report, osimertinib and other treatment records, and comparison scans. The team can assess whether tissue or blood testing would change care; a negative blood result does not necessarily exclude a targetable resistance change.

Compare options against your treatment history

• Limited-site progression and widespread progression require different assessments of local and systemic treatment.
• A treatable resistance finding or a change in histology may alter the plan; the original EGFR-positive result alone is not enough.
• Compare established options and clinical trials for the current setting, including prior platinum chemotherapy, brain-metastasis criteria and practical access.

Zidesamtinib: who the option is for

Zidesamtinib is an approved US option for adults with locally advanced or metastatic ROS1-positive NSCLC after a prior ROS1 kinase inhibitor. That treatment history matters: the indication is not a blanket first-line recommendation for every ROS1-positive cancer. Selection should consider the prior drug, pattern of progression and brain involvement, alongside monitoring for neurological effects, heart-rhythm changes and lung toxicity.

Ivonescimab: a PD-1 / VEGF bispecific antibody

Ivonescimab acts on immune suppression and blood-vessel signaling. Its lung cancer evidence covers different settings, including combinations after EGFR-targeted treatment and selected first-line populations. These are different regimens and eligibility groups. Review the exact EGFR/ALK and PD-L1 results, adenocarcinoma or squamous histology, prior medicines, bleeding risk and other contraindications. The drug guide separates evidence, approval, practical access and costs.

SKB264 / sac-TMT: a TROP2 antibody–drug conjugate

The OptiTROP-Lung04 phase III trial enrolled 376 patients with EGFR-mutated advanced non-squamous NSCLC after progression on EGFR-TKI treatment. Median progression-free survival was 8.3 months with sac-TMT versus 4.3 months with platinum-based chemotherapy. Treatment-related grade 3 or higher adverse events occurred in 58.0% versus 53.8%. These results concern that study population; prior treatment, health and the current authorized indication determine suitability. Sac-TMT is a different drug from sacituzumab govitecan.

Chirona brings relevant treatment opportunities into specialist review and coordinates the treatment location, access requirements, cost estimate and expected stay. The medicines above are not interchangeable and cannot be ranked by comparing numbers from different trials.

HER2-mutated disease

HER2-directed options are evolving. The current US sevabertinib indication covers adults with locally advanced or metastatic non-squamous NSCLC with HER2 tyrosine kinase domain activating mutations detected by an authorized test. This is an accelerated approval, with confirmatory benefit requirements; it is not an indication for any HER2 staining result. Diarrhea, liver injury, lung inflammation and cardiac effects are among the safety issues considered in prescribing.

Clinical trials

Trials may test resistance-specific medicines, antibody–drug conjugates or new immune approaches. Match the exact variant, prior treatment and allowed brain-metastasis status, and check the comparator and visit burden. Early cell-therapy or gene-editing research is not established routine NSCLC care. A registered study or overseas approval alone does not confirm local access.

Shanghai Chest Hospital · Shanghai, China

Thoracic surgery, lung medical oncology and chest radiotherapy are established specialties. This breadth is useful when comparing surgery with a nonsurgical plan, or discussing how local treatment should fit with systemic medicines.

Shanghai Pulmonary Hospital · Shanghai, China

A lung-focused center with thoracic surgery and precision oncology teams. Molecularly guided treatment, progression after prior therapy and the effect of underlying lung disease are useful questions to bring to a review.

Fudan University Shanghai Cancer Center · Shanghai, China

Its lung cancer surgery, pathology, imaging and radiotherapy services support assessment across disciplines. Consider the team when pathology review, surgical options and the sequence of combined treatment need to be considered together.

MD Anderson Cancer Center · Houston, United States

Its lung cancer program brings surgery, radiation and medical treatments into individualized plans, with molecular testing and clinical research. It is relevant when comparing several treatment approaches or seeking assessment of a clinical trial after prior treatment.

Memorial Sloan Kettering Cancer Center · New York, United States

Its lung cancer teams use tumor genetic testing to inform targeted treatment and combine surgical, radiation and medical expertise. This is useful for a treatment review that must connect a molecular result with available therapies, or compare local and systemic options.

The work-up should establish diagnosis, spread and enough relevant information to choose treatment. Depending on tumor location, sampling may use bronchoscopy, EBUS-guided lymph node biopsy, a CT-guided needle or another accessible lesion. PET-CT abnormalities sometimes need tissue confirmation; inflammation can also be active on PET.

Current lung TNM staging uses the ninth-edition/version 9 framework. Record the actual T, N and M findings and which edition the report used. Brain imaging is important in appropriate staging and symptom settings. Lung function and cardiac assessment help judge treatment tolerance independently of cancer stage.

New cough, fever or breathlessness during treatment can reflect infection, cancer or treatment-related pneumonitis and should be assessed promptly. Targeted medicines also have specific interaction and monitoring requirements; oral treatment does not mean treatment without risk. Bring all prescription medicines, supplements and over-the-counter products to the medication review.

Follow-up should state when imaging is due, what symptoms should trigger an earlier visit and whom to contact. Rehabilitation, nutrition, smoking-cessation support and palliative care can help preserve activity and comfort. Survival estimates should be interpreted with stage, molecular findings, treatment era and individual health rather than treated as a personal deadline.

A scan may find a tumor before symptoms appear. Persistent cough, blood in sputum, chest discomfort, shortness of breath or unexplained weight loss warrant assessment. Sudden severe breathlessness, substantial bleeding, seizures or new limb weakness need urgent care, because a treatable complication may be responsible.

Start with the pathology report, molecular and PD-L1 results, recent scans and reports, and a list of treatments with dates and responses. If records are incomplete, send what you have and the question you most want answered. We help identify gaps before the hospital review.

• Is the pathology sufficiently specific, and is there enough tissue for the tests that matter?
• Is the staging complete, including any lymph node or brain findings that could change the plan?
• Which exact molecular result supports this drug, and what alternatives fit the same setting?
• If treatment has failed, would tissue reassessment or a resistance test change the next decision?
• How will lung symptoms, side effects, travel and follow-up be managed?